Education
About Us
Working with TipRanks
Follow Us
Nuvalent (NUVL)
NASDAQ:NUVL
NUVL Analyst Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NUVL Stock 12 Month Forecast
Average Price Target
$118.30
▲(27.86% Upside)
| Highest Price Target$140.00 | Average Price Target$118.30 | Lowest Price Target$100.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Stifel Nicolaus
$115
Buy
24.30%
Upside
Initiated
10/16/25
Cantor Fitzgerald
$135
Buy
45.91%
Upside
Initiated
10/15/25
LifeSci Capital
$110
Buy
18.89%
Upside
Reiterated
10/13/25
Nuvalent's Promising Oncology Prospects: A Buy Rating Driven by ALKOVE-1 Trial and Market Potentials: NUVL will provide topline registraonal da ta from Phase 2 ALKOVE-1 trial by YE 2025 for neladalkib (nela) in TKI- pretreated ALK+ NSCLC. Recall that nela is a first-in-class, 4th generaon ALK inhibit or designed to overcome limitaons of prior -gen TKIs, and offers CNS acvity , TRK-sparing profile, and broader + more- potent coverage of ALK mutaons. F or the upcoming readout, NUVL plans to generate single-arm data that will include: (1) lorlanib-naiv e 2L paen ts with prior 2G TKI, (2) post-lorlanib 2L pa en ts, and (3) paen ts with any 2-3 prior ALK TKIs.
J.P. Morgan
―
Buy
―
Reiterated
10/06/25
Barclays
$100
Buy
8.08%
Upside
Reiterated
09/24/25
Raymond James
$105
Buy
13.49%
Upside
Reiterated
09/08/25
Guggenheim
$105→$122
Buy
31.86%
Upside
Initiated
09/03/25
Piper Sandler
$112
Buy
21.05%
Upside
Reiterated
08/26/25
Leerink Partners
$140
Buy
51.32%
Upside
Reiterated
08/12/25
H.C. Wainwright
$130
Buy
40.51%
Upside
Reiterated
08/08/25
TD Cowen
―
Buy
―
Reiterated
08/07/25
Goldman Sachs
―
Buy
―
Reiterated
07/03/25
Robert W. Baird
$105→$112
Buy
21.05%
Upside
Reiterated
06/25/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Stifel Nicolaus
$115
Buy
24.30%
Upside
Initiated
10/16/25
Cantor Fitzgerald
$135
Buy
45.91%
Upside
Initiated
10/15/25
LifeSci Capital
$110
Buy
18.89%
Upside
Reiterated
10/13/25
Nuvalent's Promising Oncology Prospects: A Buy Rating Driven by ALKOVE-1 Trial and Market Potentials: NUVL will provide topline registraonal da ta from Phase 2 ALKOVE-1 trial by YE 2025 for neladalkib (nela) in TKI- pretreated ALK+ NSCLC. Recall that nela is a first-in-class, 4th generaon ALK inhibit or designed to overcome limitaons of prior -gen TKIs, and offers CNS acvity , TRK-sparing profile, and broader + more- potent coverage of ALK mutaons. F or the upcoming readout, NUVL plans to generate single-arm data that will include: (1) lorlanib-naiv e 2L paen ts with prior 2G TKI, (2) post-lorlanib 2L pa en ts, and (3) paen ts with any 2-3 prior ALK TKIs.
J.P. Morgan
―
Buy
―
Reiterated
10/06/25
Barclays
$100
Buy
8.08%
Upside
Reiterated
09/24/25
Raymond James
$105
Buy
13.49%
Upside
Reiterated
09/08/25
Guggenheim
$105→$122
Buy
31.86%
Upside
Initiated
09/03/25
Piper Sandler
$112
Buy
21.05%
Upside
Reiterated
08/26/25
Leerink Partners
$140
Buy
51.32%
Upside
Reiterated
08/12/25
H.C. Wainwright
$130
Buy
40.51%
Upside
Reiterated
08/08/25
TD Cowen
―
Buy
―
Reiterated
08/07/25
Goldman Sachs
―
Buy
―
Reiterated
07/03/25
Robert W. Baird
$105→$112
Buy
21.05%
Upside
Reiterated
06/25/25
Best Analysts Covering Nuvalent
1 Month
xxx
Success Rate
8/11 ratings generated profit
Average Return
+4.62%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +4.62% per trade.
3 Months
xxx
Success Rate
6/8 ratings generated profit
Average Return
+17.77%
initiated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +17.77% per trade.
1 Year
Success Rate
10/13 ratings generated profit
Average Return
+13.40%
reiterated a buy rating 6 days ago
Copying Charles Zhu's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +13.40% per trade.
2 Years
xxx
Success Rate
14/17 ratings generated profit
Average Return
+75.55%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 82.35% of your transactions generating a profit, with an average return of +75.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NUVL Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
7
6
8
6
7
Buy
11
13
17
14
15
Hold
0
0
0
0
0
Sell
2
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
19
25
20
22
Each month's total comprises the sum of three months' worth of ratings.
NUVL Financial Forecast
NUVL Stock Forecast FAQ
What is NUVL’s average 12-month price target, according to analysts?
Based on analyst ratings, Nuvalent’s 12-month average price target is 118.30.
What is NUVL’s upside potential, based on the analysts’ average price target?
Nuvalent has 27.86% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NUVL a Buy, Sell or Hold?
Nuvalent has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Nuvalent’s price target?
The average price target for Nuvalent is 118.30. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $100.00. The average price target represents 27.86% Increase from the current price of $92.52.
The highest analyst price target is $140.00 ,the lowest forecast is $100.00. The average price target represents 27.86% Increase from the current price of $92.52.
What do analysts say about Nuvalent?
Nuvalent’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of NUVL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.